Fibromyalgia Patients Rate Lyrica High On Well-being Measures, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Also at American Academy of Neurology meeting, UCB releases data on antiepileptic lacosamide.
You may also be interested in...
Pfizer Earnings Fall 18% On Loss Of Zyrtec, Norvasc
First quarter revenues also are down 5 percent to $12.5 billion, but Lyrica and Chantix see gains.
Pfizer Earnings Fall 18% On Loss Of Zyrtec, Norvasc
First quarter revenues also are down 5 percent to $12.5 billion, but Lyrica and Chantix see gains.
Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia
Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.